Earnings summaries and quarterly performance for Adaptimmune Therapeutics.
Executive leadership at Adaptimmune Therapeutics.
Board of directors at Adaptimmune Therapeutics.
Research analysts who have asked questions during Adaptimmune Therapeutics earnings calls.
Graig Suvannavejh
Mizuho Securities
4 questions for ADAP
George Farmer
Scotiabank
3 questions for ADAP
Jonathan Chang
Leerink Partners
3 questions for ADAP
Marc Frahm
TD Cowen
3 questions for ADAP
Paul Jeng
Guggenheim Partners
3 questions for ADAP
Tony Butler
Rodman & Renshaw
3 questions for ADAP
Yu He
H.C. Wainwright & Co., LLC
3 questions for ADAP
Alexandre Bouilloux
Barclays
2 questions for ADAP
Michael Kim
Imperial Capital, LLC
2 questions for ADAP
Peter Lawson
Barclays PLC
2 questions for ADAP
Yanan Zhu
Wells Fargo Securities
2 questions for ADAP
Arthur He
H.C. Wainwright & Co.
1 question for ADAP
Matthew Cowper
Leerink Partners
1 question for ADAP
Michael Klem
Zacks Small Cap Research
1 question for ADAP
Michael Schmidt
Guggenheim Securities
1 question for ADAP
Quan Ang
Wells Fargo Securities
1 question for ADAP
Recent press releases and 8-K filings for ADAP.
- Adaptimmune Therapeutics plc received a notice from Nasdaq on September 11, 2025, indicating that its Market Value of Listed Securities (MVLS) was below the $35.0 million minimum required for continued listing on The Nasdaq Capital Market.
- The company's MVLS has been below this threshold for the last 32 consecutive business days, and it also did not meet alternative listing standards related to stockholders' equity or net income.
- Adaptimmune Therapeutics has 180 calendar days, until March 10, 2026, to regain compliance by maintaining an MVLS of at least $35.0 million for ten consecutive business days.
- Failure to regain compliance by the deadline will result in the company's American Depositary Shares (ADSs) being subject to delisting from Nasdaq.
Quarterly earnings call transcripts for Adaptimmune Therapeutics.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more